Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.

Zacks Investment Research • Aug 19, 2026

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

FORT LEE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today reported its financial results for the second quarter of 2026 and provided an update on recent business progress.

GlobeNewsWire • Aug 4, 2026

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know

The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 56.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Jul 29, 2026

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that ciprocopan (NXP100), a once-daily oral complement Factor B inhibitor, received marketing approval from the National Medicinal Products Administration of China (NMPA) for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) previously untreated with Complement inhibitors (treatment naive).

GlobeNewsWire • Jul 23, 2026

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

First global approval of a once-daily, orally administered, Complement Factor B inhibitor Approval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNH Ciprocopan application for marketing approval in China for the treatment of patients with PNH previously treated with anti-C5 therapies is currently under review Ciprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for patients requiring continuous life-long treatment Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that ciprocopan (NXP100), a once-daily oral complement Factor B inhibitor, received marketing approval from the National Medicinal Products Administration of China (NMPA) for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) previously untreated with Complement inhibitors (treatment naive). As the world's first approved once-daily oral Complement Factor B inhibitor, ciprocopan offers patients living with PNH a new, effective, safe and convenient treatment option and provides important clinical and regulatory validation and further supports the therapeutic potential of once-daily oral Factor B inhibition in PNH and other complement mediated diseases.

GlobeNewsWire • Jul 23, 2026

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco Pharmaceutical Group. Report highlights: Nuvectis Pharma (NASDAQ: NVCT) recently secured worldwide rights outside China to NXP100, a potentially best-in-class once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), along with oncology asset NXP200, from Haisco Pharmaceutical Group.

Newsfile Corp • Jul 14, 2026

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Jul 8, 2026

What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?

Does Nuvectis Pharma, Inc. (NVCT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Jul 1, 2026

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

FORT LEE, NJ, June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Nuvectis. In addition, Nuvectis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

GlobeNewsWire • Jun 29, 2026

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a price of $20.00 per share, with expected gross proceeds to Nuvectis of $100 million. Nuvectis has also granted the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about July 1, 2026, subject to satisfaction of customary closing conditions.

GlobeNewsWire • Jun 30, 2026